Aripiprazole Lauroxil
A prodrug form of aripiprazole attached to a fatty acid chain, formulated as a long-acting injectable that is slowly converted to aripiprazole over weeks following a single injection. It provides extended release to improve medication adherence in schizophrenia.
الوزن الجزيئي
660,7000 g/mol
LogP
10,00
TPSA
62,30 Ų
قاعدة ليبينسكي للخمسة
راسب
المجالات العلاجية
آلية العمل
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21
InChI
InChI=1S/C36H51Cl2N3O4/c1-2-3-4-5-6-7-8-9-10-16-35(43)45-28-41-33-27-30(19-17-29(33)18-20-34(41)42)44-26-12-11-21-39-22-24-40(25-23-39)32-15-13-14-31(37)36(32)38/h13-15,17,19,27H,2-12,16,18,20-26,28H2,1H3
Molecular Formula
C36H51Cl2N3O4
HBD / HBA
- / 6
الروابط القابلة للدوران
20
الذرات الثقيلة
45
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
A prodrug form of aripiprazole attached to a fatty acid chain, formulated as a long-acting injectable that is slowly converted to aripiprazole over weeks following a single injection. It provides extended release to improve medication adherence in schizophrenia.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Aripiprazole Lauroxil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2219425. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 49831411. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="aripiprazole-lauroxil"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/aripiprazole-lauroxil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/aripiprazole-lauroxil/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/aripiprazole-lauroxil/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="aripiprazole-lauroxil"></drugfyi-drug>